CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Raptor Pharmaceuticals Corp. (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Raptor Pharmaceuticals Corp. (OLD)
9 Commercial Boulevard
Suite 200
Novato, CA  94949  United States
This company is no longer actively traded on any major stock exchange.
Business Summary
Raptor Pharmaceuticals Corp. (Raptor) is a development-stage biotechnology company. The Company is focused on the development of new drugs. Raptor is developing drug therapies for the treatment of genetic diseases, such as Nephropathic Cystinosis (Cystinosis), Huntington’s Disease (HD), Batten Disease, metabolic diseases, including Non-Alcoholic Steatohepatitis (NASH) and Aldehyde Dehydrogenase (ALDH2), Deficiency (Ethanol Intolerance), and liver diseases, including primary liver cancer (HCC) and hepatitis. On August 1, 2007, the Company formed Bennu Pharmaceuticals Inc. (Bennu) as its wholly owned subsidiary for the purpose of developing clinical-stage drug product candidates through to commercialization. In October 2007, Raptor acquired Convivia, Inc. (Convivia).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
5/31/20098/31/2008YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
9995 Non-operating establishments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Christopher M.Starr 57 5/25/2006 5/25/2006
Chief Financial Officer, Treasurer, Secretary Kim R.Tsuchimoto 46 5/25/2006 5/25/2006
President of Raptor Therapeutics Inc. Thomas E.Daley 46 9/10/2007 9/10/2007
5 additional Officers and Directors records available in full report.

General Information
Stock Exchange: OTC
Federal Tax Id: 980379350


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023